Search

Your search keyword '"Lundman P"' showing total 11 results
Start Over Author "Lundman P" Journal european heart journal
11 results on '"Lundman P"'

5. P6599Upregulation of protein and gene expression of arginase-1 in patients with ST elevation myocardial infarction

Author

Tengbom, J, primary, Cederstrom, S, additional, Verouhis, D, additional, Sorensson, P, additional, Bohm, F, additional, Saleh, N, additional, Jernberg, T, additional, Lundman, P, additional, Eriksson, P, additional, Gabrielsen, A, additional, Caidahl, K, additional, Persson, J, additional, Folkersen, L, additional, Tornvall, P, additional, and Pernow, J, additional

Published
2019
Full Text
View/download PDF

11. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.

Author

Allahyari A, Jernberg T, Hagström E, Leosdottir M, Lundman P, and Ueda P

Subjects
Adolescent, Adult, Aged, Ezetimibe therapeutic use, Female, Humans, Middle Aged, PCSK9 Inhibitors, Young Adult, Anticholesteremic Agents therapeutic use, Atherosclerosis, Cardiology, Dyslipidemias drug therapy, Dyslipidemias epidemiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Myocardial Infarction drug therapy, Percutaneous Coronary Intervention
Abstract

Aims: To estimate the proportion of patients with a recent myocardial infarction (MI) who would be eligible for additional lipid-lowering therapy according to the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines for the management of dyslipidaemias, and to simulate the effects of expanded lipid-lowering therapy on attainment of the low-density lipoprotein cholesterol (LDL-C) target as recommended by the guidelines., Methods and Results: Using the nationwide SWEDEHEART register, we included 25 466 patients who had attended a follow-up visit 6-10 weeks after an MI event, 2013-17. While most patients (86.6%) were receiving high-intensity statins, 82.9% of the patients would be eligible for expanded lipid-lowering therapy, as they had not attained the target of an LDL-C level of <1.4 mmol and a ≥50% LDL-C level reduction. When maximized use of high-intensity statins followed by add-on therapy with ezetimibe was simulated using a Monte Carlo model, the LDL-C target was reached in 19.9% using high-intensity statin monotherapy and in another 28.5% with high-intensity statins and ezetimibe, while 50.7% would still be eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. When use of alirocumab or evolocumab was simulated in those who were eligible for PCSK9 inhibitors, around 90% of all patients attained the LDL-C target., Conclusion: Our study suggests that, even with maximized use of high-intensity statins and ezetimibe, around half of patients with MI would be eligible for treatment with PCSK9 inhibitors according to the 2019 ESC/EAS guidelines. Considering the current cost of PCSK9 inhibitors, the financial implications of the new guidelines may be substantial., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results